In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $81.00. The company’s shares closed last Monday at $76.37.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.8% and a 58.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Freeline Therapeutics Holdings, and BioMarin Pharmaceutical.
Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $98.31, which is a 31.9% upside from current levels. In a report issued on April 12, Mizuho Securities also maintained a Hold rating on the stock with a $81.00 price target.
The company has a one-year high of $98.39 and a one-year low of $30.33. Currently, SAGE Therapeutics has an average volume of 478.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.